Plymouth Meeting, PA – August 25, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, announces that it has been selected as a partner of choice by two top tier pharmaceutical companies to support their highest priority drug development initiatives.
The agreements encompass two exclusive multi-year drug development initiatives covering 75 countries, 2,500 clinical research sites and more than 10,000 clinical trial participants. CRF Health’s TrialMax® platform will underpin both projects. The TrialMax Touch® handheld patient diary and the site-based TrialMax Slate® will be used in combination with the TrialMax Web® solution, allowing both sponsors to drive data collection across all requirements while supporting the collection of medication management data.
“We are delighted to have been selected to be part of these two critical projects”, comments John Blakeley, Chief Business Officer at CRF Health. “The rapid pace of technology development and relatively low cost of moving data globally is enabling biopharmaceutical companies to leverage robust data collection from patients and sites, which is driving high compliance rates and helping to lower overall development costs. We believe the use of electronic collection techniques is rapidly becoming the standard across the globe”.